New data from Novo Nordisk’s Phase III ESSENCE study of semaglutide in non-alcoholic steatohepatitis (NASH) unveiled at the American Association for the Study of Liver Disease conference on 19 November showed that the GLP-1 agonist performed better than Madrigal’s Rezdiffra (resmetirom), the only approved NASH drug, in an analysis combining outcomes on the two primary endpoints, reduction of liver fibrosis and resolution of NASH.
Novo Nordisk’s Semaglutide Tops Madrigal’s Rezdiffra In NASH
Greater Combined Effect Seen In Phase III Trials
The firm revealed that an analysis of its Phase III ESSENCE trial combining fibrosis reduction and NASH resolution showed a higher effect over placebo than in Madrigal’s pivotal trial.
